In this video, we take a look at two of the biggest and most important companies in the biotech space. Both are reporting earnings this week, and given the volatile nature of the sector lately, it will definitely be in investors' best interest to see how two of the top dogs in this market fare in their quarterly reports.
After all, the space is likely to face some political risks with the upcoming election, while there are definitely valuation concerns. And given a top 30% industry rank, there are going to be plenty of stocks to buy in this space, but also a few to avoid too.
First, let's take a quick look at Gilead Sciences GILD, a California-based giant with a market cap over $100 billion. The stock currently has a Zacks Rank #2 (buy), while it has an ‘A' Score for its VGM, so fundamentals are pretty impressive. However, it did just miss estimates to break its impressive streak, while growth rates aren't that inspiring, making this a real mixed bag heading into earnings.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GILEAD SCIENCES GILD: Free Stock Analysis Report
AMGEN INC AMGN: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.